CJC-1295/Ipamorelin

Clinical Trials

Growth Hormone

A powerful growth hormone releasing combination that stimulates natural GH production for anti-aging, muscle growth, and fat loss.

Administration

Subcutaneous injection

Dosage Range

CJC-1295: 1-2 mg weekly; Ipamorelin: 200-300 mcg before bed

Mechanism of Action

CJC-1295 is a GHRH analog that extends GH release duration, while Ipamorelin is a selective ghrelin mimetic that triggers GH pulses. Together they amplify natural GH secretion without disrupting other hormones.

Clinical Benefits

Increases lean muscle mass

Reduces body fat

Improves sleep quality

Enhances recovery from exercise

Supports bone density

Anti-aging effects on skin and hair

Clinical Evidence

CJC-1295 has demonstrated sustained GH elevation for 6-8 days in human trials. Ipamorelin shows selective GH release without cortisol or prolactin elevation in Phase II trials.

Side Effects

Water retention

Tingling/numbness in extremities

Increased hunger

Mild headache

Contraindications

Active cancer

Diabetes (monitor closely)

Pregnancy

Related Peptides in Growth Hormone

Tesamorelin

An FDA-approved GHRH analog that reduces visceral adipose tissue and improves body composition, particularly in lipodystrophy.

Sermorelin

A GHRH analog that stimulates natural growth hormone production, widely used for anti-aging and growth hormone optimization.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.